New York, November 18, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Molecular Diagnostics Market – A Global and Regional Analysis: Focus on Product, Test Location, Application, Technology and ‘End User – Analysis and Forecast, 2021-2031 “- https://www.reportlinker.com/p06184570/?utm_source=GNW
• Products (kits and consumables, systems, software and other products)
• Test location (laboratory and point-of-care (POC) testing)
• Application (basic molecular diagnostics, reproductive genetics, companion diagnostics (CDx), liquid biopsy and others)
• Technology (polymerase chain reaction (PCR), next generation sequencing, isothermal nucleic acid amplification technology (INAAT), microarray, in situ hybridization (ISH), immunohistochemistry (IHC) and other technologies)
• End user (hospitals, diagnostic centers, outpatient clinics / general practitioners, research laboratories and other end users)

Regional segmentation

• North America: United States, Canada
• Europe: Germany, France, Italy, United Kingdom, Spain and rest of Europe
• Asia-Pacific: Japan, China, India, Australia, Singapore and rest of Asia-Pacific
• Latin America: Brazil, Mexico, rest of Latin America
• Rest of the world (RoW)

Market growth drivers

• A very increasing prevalence of infectious diseases and various types of cancer, worldwide
• Growth of the biomarker identification market and progress in molecular techniques
• Increased awareness and acceptance of personalized medicines globally
• Significant external funding for the execution of research and development exercises

Market challenges

• Uncertain repayment scenario
• Lack of high complexity test centers
• Complex regulatory frameworks delaying approval of new molecular diagnostic tests

Market opportunities

• Massive reach for the adoption of molecular diagnostics in emerging countries
• The rise of new generation ultra-sensitive molecular diagnostics
• New sources of income

Key companies profiled

Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Guardant Health, HTG Molecular Diagnostics, Inc., Illumina, Inc., Invivoscribe, Inc., ICON plc, LungLife AI, Inc., QIAGEN, QuantuMDx Group Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc.

Key questions addressed in this report:
• How is each market segment expected to grow during the forecast period 2021-2031, and what is the expected revenue generated by each segment?
• What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
• What are the underlying structures driving emerging trends in the global molecular diagnostics market?
How is each segment of the global molecular diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
• What are the key development strategies implemented by the main players to remain in the competitive market?
• What are the main regulatory implications in developed and developing regions for molecular diagnostics?
• Who are the main players offering significant offers in the global molecular diagnostics market? What is the current market dominance for each of these major players?
• What would be the compound growth rate observed by major market players during the forecast period 2021-2031? What type of molecular diagnostic product is experiencing the most promising growth?
• What are the key applications in the global molecular diagnostics market? What are the major segments of these applications? What technologies dominate these application segments?
• What are the major technologies used in the global molecular diagnostics market? What is the dominant technology?
• Who are the major end-users of the global molecular diagnostics market? What is the fastest growing end-user segment in the global molecular diagnostics market?
• Who are the major manufacturers in the global molecular diagnostics market and what are their contributions? Additionally, what is the growth potential of each major manufacturer of molecular diagnostics?
• What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America and the rest of the world? Which molecular diagnostic application and which end user dominates in these regions?
• What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
• What technologies should break through the current molecular diagnostic regime?
• Which companies are expected to be very disruptive in the future and why?
• What are the regulatory procedures required to unify the approval process for emerging molecular diagnostics? How will these improve the repayment scenario?
• What are the gaps in regulating optimal uptake of molecular diagnostics into health care routines? How are these gaps filled?

Market Snapshot

Diagnostic tests provide essential information at every stage of medical care – from genetic tests providing information about personalized cancer treatment to microbial culture identifying specific antibiotics against infection. The importance of diagnostic testing throughout the procedure (i.e. prevention, detection, diagnosis, treatment and successful management of health problems) of an individual’s treatment for a disease particular is as important as the treatment itself. It has been extensively researched to refine it further.

Our health experts have found that the molecular diagnostics market is one of the stable markets, and the global market is expected to grow from $ 10,914.6 million in 2020 to $ 24,228.0 million in 2031 and is expected to grow with a CAGR of 7.38% over the forecast period. 2021-2031.

Factors fueling the growth of the market include a very increasing prevalence of infectious diseases and various types of cancer, an increase in awareness and acceptance of personalized drugs globally, and significant external funding for the execution of exercises. research and development. growth, several key issues need to be addressed to facilitate future growth.

Uncertain reimbursement scenarios, lack of high complexity test centers, and complex regulatory frameworks delaying approval of new molecular diagnostic tests are hampering market growth. In addition, some of the opportunities, such as the vast scope of adoption of molecular diagnostics in emerging countries and the rise of next-generation ultra-sensitive molecular diagnostics and new revenue streams, are driving the market growth.

In the research report, the market has been segmented on the basis of product, testing location, application, technology, end user, and region. Each of these segments covers the market snapshot over the projected years, market revenue tilt, underlying patterns and trends using analyzes on the obtained primary and secondary data.

Competitive landscape

The exponential increase in the prevalence of infectious diseases and various types of cancer globally has created a buzz among companies to invest in advanced technologies such as molecular diagnostics.

Based on region, North America holds the largest share, due to improved health infrastructure, increased per capita income, and improvised reimbursement policies in the region. However, Asia-Pacific and Europe regions are expected to grow at the fastest CAGR during the forecast period.

Covered countries
• North America
• WE
• Canada
• Europe
• Germany
• Italy
• France
• UK
• Spain
• The rest of Europe
• Asia Pacific
• China
• India
• Singapore
• Japan
• Australia
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Rest of the world (RoW)
Read the full report: https://www.reportlinker.com/p06184570/?utm_source=GNW

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________